15-Year watch: tracking Long-Term effects of groundbreaking cancer therapy

NCT ID NCT06785818

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is a long-term safety registry for patients in South Korea who have received Kymriah (tisagenlecleucel), a type of CAR-T cell therapy, for certain B-cell blood cancers. It will follow 500 patients for 15 years to monitor for any long-term side effects, including the risk of new cancers, and to see how well the treatment continues to work over time. The goal is to better understand the real-world, long-term safety and effectiveness of this advanced therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Bundang Gu, Gyeonggi-do, 13620, South Korea
Novartis Investigative Site
RECRUITING

Seongnam-si, Gyeonggi-do, 463-712, South Korea
Novartis Investigative Site
RECRUITING

Gyeonggi-do, Korea, 10408, South Korea
Novartis Investigative Site
RECRUITING

Incheon, Korea, 405 760, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Korea, 02841, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Korea, 03080, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Korea, 08308, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Seoul, 06351, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Seoul, 150-713, South Korea
Novartis Investigative Site
RECRUITING

Busan, 49201, South Korea
Novartis Investigative Site
RECRUITING

Jeollanam, 519763, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03722, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 04401, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 05505, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 06591, South Korea
Novartis Investigative Site
RECRUITING

Ulsan, 44033, South Korea

Conditions

Explore the condition pages connected to this study.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA